Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

J Clin Pharmacol. 2001 Oct;41(10):1106-10. doi: 10.1177/00912700122012715.

Abstract

To assess dose proportionality of etoricoxib across the anticipated clinical dose range, a single panel of 12 healthy subjects was administered single oral doses of etoricoxib of 5, 10, 20, 40, and 120 mg in an open, two-part, five-period crossover study. Plasma samples were collected aftereach dose and analyzed for etoricoxib concentrations. The pharmacokinetics of etoricoxib appear to be linear over the entire dose range examined, from 5 to 120 mg. Etoricoxib was found to be well tolerated across the 5 to 120 mg dose range.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Analysis of Variance
  • Area Under Curve
  • Cross-Over Studies
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / administration & dosage*
  • Cyclooxygenase Inhibitors / adverse effects
  • Cyclooxygenase Inhibitors / blood
  • Dose-Response Relationship, Drug
  • Etoricoxib
  • Female
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Male
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases
  • Pyridines / administration & dosage*
  • Pyridines / adverse effects
  • Pyridines / blood
  • Sulfones / administration & dosage*
  • Sulfones / adverse effects
  • Sulfones / blood

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Pyridines
  • Sulfones
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Etoricoxib